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Abstract 
 
Using quantitative PCR-based miRNA arrays, I have comprehensively analyzed the 
expression profiles of miRNAs in human and mouse embryonic stem (ES), induced 
pluripotent stem (iPS), and somatic cells. Immature pluripotent cells used for miRNA 
profiling were purified using the SSEA-1 or SSEA-4 antibody. Hierarchical clustering 
and consensus clustering by nonnegative matrix factorization showed separation of two 
major clusters, human ES/iPS cells and other cell groups, as previously reported. 
Principal components analysis (PCA) that segregates miRNAs into these two groups 
identified miR-187, 299-3p, 499-5p, 628-5p, and 888 as new miRNAs that specifically 
characterize human ES/iPS cells. Detailed direct comparisons of miRNA expression 
levels in human ES and iPS cells showed that several miRNAs included in the 
chromosome 19 miRNA cluster were more strongly expressed in iPS cells than in ES 
cells. Similar analysis was conducted with mouse ES/iPS cells and somatic cells, and 
several miRNAs were suggested to be  ES/iPS cell-specific, which have not been reported 
to be expressed in mouse ES/iPS cells. ES/iPS cells in humans and mice showed quite 
similar average expression levels of miRNAs. Expression levels of miRNA showed 
drastic and different patterns of changes during embryoid body formation. In summary, 
my miRNA expression profiling, encompassing human and mouse ES and iPS cells, 
would give various perspectives in understanding the miRNA core regulatory networks 
which regulate the characteristics of pluripotent cells. 
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Abbreviations 
 
miRNA microRNA 
ES  embryonic stem 
iPS  induced pluripotent stem 
SSEA-1 stage-specific embryonic antigen-1/ CD15 
SSEA-4 stage-specific embryonic antigen-4 
b-FGF  basic fibroblast growth factor 
EGF  epidermal growth factor 
TGF-β   transforming growth factor-β 
LIF  leukemia inhibitory factor 
OSKM  Oct3/4, Sox2, Klf4, c-myc 
C19MC chromosome 19 miRNA cluster 
HC  Hierarchical clustering 
NMF  Non-matrix factorization 
PCA  Principal component analysis 
PC  Principal Component 
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Introduction 
 
Pluripotent stem cells were first discovered in the inner cell mass of blastocyst-stage 
embryos [1]. Embryonic stem (ES) cells can be expanded in vitro while maintaining its 
undifferentiated properties and possessing the capacity to differentiate into various types 
of cells. The unique pluripotent characteristics offered by ES cells bring hope to the goal 
of regenerative medicine; generation of tissues or organs in vitro and usage in the 
treatment of various diseases. However, utilization of ES cells for clinical purposed is 
challenging due to several ethical issues pertaining to the used of embryos. To tackle this 
issue, a group from Kyoto University has identified a set of transcription factors that’s 
responsible for the maintenance of ES cells identity. The human-made pluripotent cells 
which were first reprogrammed from mouse somatic cells with the introduction of Oct3/4, 
Sox2, Klf-4, and c-Myc (OSKM) were then termed as induced pluripotent stem (iPS) 
cells [2]. The OSKM are pluripotent associated transcription factors that are conserved 
between mouse and human, and were shown to successfully reprogram fibroblast cells to 
iPS cells [2, 3]. The use of OSKM has been shown to cause global reversion of the 
somatic epigenome to ES cell state, resulted in the generation of iPS cells that are 
epigenetically similar to ES cells in terms of the expression of cell surface markers, 
differentiation capacity, teratoma formation, germline transmission and chimera 
development [4]. These criteria are phenotypically used to define or distinguish ES and 
iPS cells from somatic cells. 
Thanks to the great potential offer by iPS cells, rapid progresses have been done in 
investigating the capacity of other somatic cells to be reprogrammed into pluripotent 
cells. Several studies have explored the use of neural stem cells [5], blood cells [6], renal 
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tubular cells from urine [7], and others as a promising source to generate iPS cells in 
human. On the other hand, several groups are also focusing on the improvement of the 
reprogramming efficiency by using small molecule or chemical compounds such as 
valproic acid [8] and vitamin C [9] that alter DNA methylation or histone modification. 
Furthermore, studies on improving the methods of delivering the reprogramming factors 
have received a lot of attention. The reprogramming delivery systems are now not limited 
to only retrovirus [2], but expanded to the use of lentivirus [10], adenovirus [11], sendai 
virus [12], small RNA [13] and recombinant protein [14]. 
However, differences in the choice of somatic cells sources and reprogramming methods 
could cause the variations among iPS cells and affect the application of iPS cells, 
particularly for the clinical use. On the other hand, many studies have focused on the 
examination of the regulatory networks linking chromatin structure and gene expression 
programs [15], as well as mRNA and microRNA (miRNA) expression profiles [15,16] of 
iPS cells and ES cells, and improved the understanding of genomic and epigenomic 
networks underlying reprogramming, self-renewal, and cell fate decisions. One regulatory 
component that has received increasing attention is miRNAs. A miRNA is transcribed 
from a miRNA gene into a primary miRNA with stem loop structure, followed by 
generation of a 60-70 nt long precursor miRNA (pre-miR) before forming a mature 
miRNA with 18-22 nt. Mature miRNAs have the ability to regulate many target genes 
and control gene expression through the translational repression and degradation [17]. 
miRNAs are expressed at different levels in a wide range of cells, including ES [18-20], 
iPS [21], and somatic cells [21]. Differential expression of miRNAs can be used as 
markers to classify cell types such as iPS and ES cells. Previous studies have identified 
several stem cell-specific miRNAs that are expressed abundantly in human and mouse 
 6 
pluripotent cells. This includes members of the miR-302 cluster [20-23], which are 
transcribed as a single transcript from the same miRNA cluster and highly related to each 
other. Other known stem cell-specific miRNA clusters are the chromosome 19 microRNA 
cluster (C19MC) including miR-517a, miR-519b, miR-520b, miR-520b, and miR-521 
which are highly expressed only in human stem cells [18], and the miR-290 cluster with 
high expression levels in mouse stem cells [19].   
Considering the importance of miRNAs to serve as a cell signature, I further focused on 
the identification of new miRNAs that can be used to define the pluripotency in ES and 
iPS cells. The identification of new miRNAs is important to improve the current 
understanding of miRNA regulation in regards to the reprogramming, maintenance of the 
self-renewal and determination of cell lineage. The selection of method is very crucial to 
obtain a reliable miRNA profiling and miRNAs can be detected by various methods such 
as sequencing [18], Northern blot [19], microarray [20,21], and others. Each technique 
has its advantages and disadvantages; sensitivity, cost, sequence dependence, and 
possible artifact from contamination. Therefore, different approaches and/or experimental 
settings may result in different miRNA expression profiling. 
The miRNA profiling of pluripotent and differentiated cell lines of human and mouse 
cells has not been analyzed yet at the same time. In this study, I took the advantage of the 
miRNA array system with optimized experimental settings to improve the current 
understanding of miRNA profiles in both pluripotent and non-pluripotent cells. I 
identified new miRNAs, which are specific to pluripotent cells from human, and mouse. I 
also focused on the miRNAs that can be used to distinguish between human and mouse, 
which will provide an insight into the similarity and differences between the human and 
mouse pluripotent cells in term of miRNA expression profiles.  
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Materials and Methods 
Culture of pluripotent stem cells 
Human ES and iPS cell lines were used in conformity with the guidelines for derivation 
and utilization of human ES cells outlined by The Ministry of Education, Culture, Sports, 
Science and Technology, Japan. The human ES (HUES3) was kindly provided by Dr. 
Michiue (the Uni. of Tokyo). Other human pluripotent cell lines were provided by Stem 
Cell Bank of Institute of Medical Science, The University of Tokyo. The human 
pluripotent cells used in this work were previously published, and are listed in Table 1 
with references. Human iPS cells were maintained as described previously with some 
modification [2]. Briefly, human iPS and two human ES (khES3, H1) cells were 
maintained in DMEM/F12 (Sigma) supplemented with 20% knockout serum replacement 
(Invitrogen), 1% MEM non-essential amino acid (Invitrogen), 1% L-Glutamine 
(Invitrogen), 0.2% 2-mercaptoethanol (Invitrogen) and 5ng/ml basic-FGF (Upstate). For 
splitting cells, 0.05% Trypsin-EDTA (Sigma) was used with or without 10µM Rock 
inhibitor (TOCRIS). Other human ES cells (HUES3, HUES8, and HUES10) were 
maintained under feeder free condition as previously described [25] with modification. 
Cells were dissociated using CTK solution (ReproCells). All human ES and iPS cells 
were maintained, and sorted for RNA analysis by members of the Stem Cell Bank. 
The B6 iPS#1 and #3 (unpublished) were kindly provided by Prof. Nakauchi and Dr. Otsu 
(Institute of Medical Science, The University of Tokyo). The SP_miPS and Nanog-iPS38 
cells were proved by Prof. Yamanaka (Kyoto University). The mouse ES cells (CCE) was 
kindly provided by Dr. Nichikawa (CDB) while K3 B6 and ES_RED were provided by 
Stem Cell Bank (Institute of Medical Science, The University of Tokyo). The mouse iPS 
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cells were maintained in iPS medium consisting of DMEM high glucose (GIBCO), 15% 
fetal calf serum (GIBCO), 2% HEPES buffer solution (Nacalai Tesque), 1% L-glutamine 
(Nacalai Tesque), 1% non-essential amino acid (GIBCO), penicillin/streptomycin (P/S), 
1000 U/ml of Leukemia Inhibitory Factor (ESGRO, Chemicon), and 0.2% β-
mercaptoethanol (SIGMA). The cells were cultured on 0.1% gelatin-coated plates with 
monolayer of mitomycin-C treated mouse embryonic fibroblast (MEF). Mouse ES cells 
(ES_K3_B6 and ES_RED) were cultured in the same culture conditions as iPS cells while 
ES_CCE was cultured in the same culture medium but without the feeder cells. 
 
Preparation of mouse embryonic fibroblasts (MEF) and tail-tip fibroblasts (TTF) 
MEF and TTF were isolated and described in detail in previous paper [2]. Briefly, MEF 
were obtained by mincing the E12 embryo without internal organs followed by digestion 
in 0.05% trypsin-EDTA, and strained through 70 µm cell strainer (Falcon, BD 
Bioscience). Single cells obtained were cultured until confluence. TTF were obtained 
from adult tail tip by culturing tailbone that was cleaned by removing surrounding muscle 
and skin. The cleaned bones were then placed on the culture dish and medium was 
carefully added to the dish. The tail-tip was left undisturbed for two days before fresh 
medium was added. MEF and TTF were maintained in DMEM (Nacalai Tesque) 
supplemented with 10% FCS and 0.5% penicillin/streptomyci 
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Table 1 Cell lines used in this study 
Sample name Abbreviation Reprogramming conditions Cell source 
Cell 
condition Ref 
Undifferentiated human embryonic stem cells (hES cells) 
HUES3 HUES3 - female P26-3-3 sen 58 
HUES8 HUES8 - female P17-4-7, TELA 58 
HUES10 HUES10 - female P12-13, TELA 58 
KhES-3 khES3, khES3_RI - female +/- RI - 
HI H1 - female P57 59 
Undifferentiated human induced pluripotent stem cells (hiPS cells), all cells were sorted by SSEA-4 
tkDA 3-4 DA, DA_RI OSKM, retroV adult dermal fibroblasts +/- RI 65 
TkCB 7-4 CB, CB_RI OSKM, retroV cord blood +/- RI 65 
tkCB Sev9 CB_sev9 OSKM, Sendai V cord blood  65 
tkPB Sev2 PB OSKM, Sendai V peripheral blood, CD34-rich  65 
tkDN 4-M DN OSK, retroV neonatal dermal fibroblasts  65 
TkT 3 V1-7 TKT OSK, retroV peripheral blood T cells  60 
H25 4 Sev H254 OSKM, Sendai V CD8+ T cell clone  60 
Embryoid bodies (EBs) and somatic cells 
tkCB7-1 EBd7 EB_d7 - Differentiated 
from tkCB7-1 iPS 
- - 
tkCB7-1 EBd14 EB_d14 - - - 
tkCB7-1 EBd21 EB_d21 - - - 
HEK293 HEK293 - human embryonic kidney 293 - 61 
HeLa HeLa - Adenocarcinoma cervix cell line - 62 
Y79 Y79 - Retinoblastoma cell line - 26 
HDF Adult HDF_AD - Dermal fibroblast 
cell 
- - 
HDF Neonatal HDF_N - - - 
PBMC_M PBMC_M - Peripheral blood 
mono nuclear 
cells 
  
PBMC_T PBMC_T -  - 
tkDA3-4 NSC DA_NSC - Neural stem cells from tkDA3-4 iPS - - 
tkCB Sev9 NSC CB_NSC - 
Neural stem cells 
from tkCB Sev9 
iPS 
- - 
Undifferentiated mouse embryonic stem cells (miPS cells), all cells were sorted by SSEA-1 
CCE ES_CCE - 129S6/SyEyTac  1 
K3 B6 ES_K3_B6 - 129Sv x B6  - 
(2)RED2i ES_RED - 129S6/B6-F1  63 
Undifferentiated mouse induced pluripotent stem cells (miPS cells), all cells were sorted by SSEA-1 
SP miPS SP_iPS OSKM, retroV MEF (B6)  65 
Nanog-ips 38 Nanog_iPS OSKM, retroV MEF (B6) Sorted GFP+ - 
B6 iPS#1 B6_iPS_1 OSKM, retroV MEF (B6)  - 
B6 iPS#3 B6_iPS_3 OSKM, retroV MEF (B6)  - 
Embryoid bodies and others 
EB_ SP  EB_SP_iPS - SP miPS Day 15 EBs - 
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EB_ Nanog 38 EB_Nanog_iPS - Nanog-38 ips Day 15 EBs - 
mouse embryonic 
fibroblast MEF  ICR  64 
tail tip fibroblast TTF  ICR  - 
Abbreviation: OSKM; Oct3/4, Sox2, Klf4, c-Myc, retroV; retrovirus, sendai V; sendai 
virus, RI; Rock Inhibitor 
 
 
Culture of cell lines, primary cells, and preparation of PBMC 
HeLa and HEK293 cells were maintained in DMEM (Nacalai Tesque) supplemented with 
10% FCS and 0.5% penicillin/streptomycin. Y79 [26] was obtained from the Riken Cell 
Bank (identification number RCB1645) and maintained in RPMI1640 (Nacalai Tesque) 
supplemented with 10% FCS and penicillin/streptomycin. Peripheral blood mononuclear 
cells (PBMC) were prepared by members of Stem Cell Bank (Institute of Medical 
Science, University of Tokyo) using a standard density gradient-separation technique. 
Documented informed consent was obtained. This study has been performed according to 
the Declaration of Helsinki, and the process involved has also been approved by the 
institutional review board (Institute of Medical Science, University of Tokyo Ethics 
Committee reference No. 20-8-0826). Human adult and fetal dermal cells (HDF_AD and 
HDF_N) were purchased from Cell Applications Inc. through Japanese trader TOYOBO 
and maintained in DMEM supplemented with 10% FBS, L-glutamine and 0.5% 
penicillin/streptomycin. 
 
Neural induction of human iPS cells 
We prepared neural induction according to protocol that was described previously [27] 
Briefly, human iPS cell cultures were dissociated using 0.25% trypsin, and plated on 
gelatin for 1 h at 37°C in the presence of Rock inhibitor (Y-27632, Wako) to remove 
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MEF. The nonadherent iPS cells were plated on Matrigel (Becton, Dickinson and 
Company) coated dishes at a density of 10,000 cells/cm2 in MEF-conditioned iPS-
medium supplemented with 10 ng/ml of b-FGF (Peprotech) and Rock inhibitor. The iPS 
cells were allowed to expand for 3 days, and the initial differentiation was induced by 
replacing media with knockout serum replacement media supplemented with 10 µM 
TGF-β inhibitor (SB431542, Tocris) and 200 ng/ml of Noggin (R&D). From day 4, 
increasing amounts of N2/B27 medium (Neurobasal, 1% N2 supplement, 2% B27 
supplement, 1% L-Glutamine, P/S) was added to the culture every 2 days (25%, 50%, 
75%). Upon day 10 of differentiation, cells were passaged en bloc onto Matrigel-coated 
dishes in N2/B27 media supplemented with 10 ng/ml b-FGF and 10 ng/ml EGF. The 
growing cells were dissociated and passaged every 7-10 days in the N2/B27 media 
supplemented with b-FGF and EGF. To examine neurogenic potential of these cells, 
differentiation was induced by the removal of growth factors and the addition of FCS. 
Multi-lineage differentiation was confirmed by immunostaining of neuronal (βIII tubulin) 
and astroglial (S-100β) markers, thereby iPS-derived cells were defined as neural 
stem/progenitor cells (NSCs). 
 
Preparation of immature pluripotent cells  
We cultured human and mouse iPS cells at appropriate density and were grown 
exponentially on 6-cm dishes containing pre-irradiated MEF feeder cells. On day 4 or 5, 
the cells were harvested by trypsinization and stained with anti-SSEA-4 (for human cells) 
or -SSEA-1 (for mouse cells) antibodies. Subsequently, the SSEA-4 or SSEA-1 positive 
cells (5x105 cells/tube) were sorted by FACS (Moflo, Dako Cytomation) into collection 
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tubes containing 200 µl of 2.5% FCS in PBS. Cells were immediately collected as pellets 
by centrifugation,  snap frozen in liquid nitrogen, and stored at -80°C until used. Mouse 
ES, CCE cells are cultured in feeder free system. Feeder free culture of human ES cells 
were done by Dr. Michiue (Univ. Tokyo). 
 
Preparation of embryoid bodies (EBs)  
EB formation of human iPS cells was carried out following previously reported 
procedures [28]. The EBs were harvested at day 7, 14 and 21, stained and sorted for 
SSEA-4 negative cell by members of the Stem Cell Bank. Mouse EBs were obtained by 
culturing iPS cells on a petri dish in the absence of LIF. Briefly, iPS cells were detached 
and collected cells were cultured for 30 minutes in a gelatin coated tissue culture dish to 
separate iPS cells from MEF feeder cells. Then, suspension cells were collected and 
further cultured as suspension in non-coated petri dishes. At day 15 of differentiation, 
cells were harvested, stained and sorted for SSEA-1 negative cells. Cells were all 
prepared under RNase-free condition. 
 
RNA extraction and miRNA examination 
Total RNA was extracted according to the manufacturer protocol using miRVana miRNA 
isolation kit (Ambion). In some cases as noted in the manuscript, cells were underwent 
RNA purification using RNeasy Plus Micro Kit (Qiagen). RNA (500 ng) was reverse 
transcribed using Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) 
and Megaplex RT primers Human Pool A or Rodent Pool A (Applied Biosystems). Then, 
cDNA was mixed with EagleTaq Master Mix with Rox (ROCHE) and was dispensed into 
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each port of the TaqMan human or rodent MicroRNA Array A card v2.0 (Applied 
Biosystems). Human Array A card contains primers for 381 miRNAs including 3 positive 
control miRNAs, and 1 negative control primer. Rodent Array A card contains 341 
primers for mouse miRNAs including 5 positive control miRNAs, and 1 negative control 
primer. Each miRNA card was run for real-time PCR using ABI PRISM 7900 HT 
Sequence Detection System (Applied Biosystems). The results were analyzed with SDS 
2.4 and RQmanager 1.2.1 software (Applied Biosystems).  
 
Data Analysis 
Hierarchical clustering (HC), non-negative matrix factorization (NMF) and principal 
component analysis (PCA) were done using MeV 4.8.1 (Multi Experiment Viewer) 
software (http://www.tm4.org/mev/) according to the manufacturer’s instruction. The 
miRNAs expression data was clustered using average hierarchical clustering using 
Euculidean distance. Average value of distance of each miRNA was used to measure the 
cluster-to-cluster distance.  NMF [29] was computed on miRNA expression profiles. We 
determined the minimum number of metaprofiles necessary to separate pluripotent cells 
from differentiated cells. PCA [30] was carried out on all genes under investigation to 
determine expression trends within the samples. A sample trend is shown in a scatter plot 
of the principal components PC1, PC2 and PC3. 
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Results 
miRNA Expression Profiling of Pluripotent Stem Cells Using Quantitative PCR Arrays  
To perform a comprehensive profile of miRNA expression patterns in human pluripotent 
stem cells, I used six ES cell lines, nine iPS cell lines, EBs at three different time points 
from one iPS cell line, two iPS cell-derived NSCs, and four primary tissues. Three cancer 
cell lines were also used as control somatic cells. For mouse samples, I profiled three ES 
cell lines, four iPS cell lines, two iPS-derived EBs, MEF, and TTF. The human iPS cells 
were generated by three or four reprogramming factors, and were transduced using 
different delivery methods and source of cells (Table 1). I used human and mouse arrays 
covering 377 and 335 miRNAs, respectively.  
To begin with, I optimized a protocol to prepare cells for the accurate examination of 
miRNA expression patterns. Since some of the iPS and ES cells were cultured on MEF 
feeder cells, I examined whether the purification of the iPS cells is necessary or not. I 
compared the miRNA expression profiles of the unsorted and the sorted iPS cells using 
The SSEA-4 or SSEA-1 antibody. The miRNA expression profiles using the purified 
samples gave lower Ct values in the most of the miRNAs analyzed. This indicated that 
the contamination of the RNA from feeder cells reduced the sensitivity of detection. 
Hence, I purified human and mouse pluripotent cells with the SSEA-4 or  SSEA-1 
antibody before subsequent analysis in this study. 
Next, I validated the reproducibility of the qPCR array method, and analysed the miRNA 
expression patterns of three independent samples from tkCB7-4 cells using the human 
array. They showed good reproducibility, especially for the miRNAs known to be 
expressed at relatively high levels in pluripotent cells. In summary, there were 124 
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miRNAs with average ΔCt values of less than 10, 115 miRNAs of which showed 
standard deviations (SD) of less than 1. Although nine miRNAs showed SD more than 10, 
they were caused by false negative or false positive samples. Due to the high 
reproducibility of this methods, all data were taken from single experiment  
Average ΔCt values for miRNAs were compared between human ES and iPS cell group 
(hES/hiPS-g) and the somatic cell, cancer cell, and NSC group (hSomatic-g). I found 
statistically significant differences between the two groups and listed the top 50 miRNAs 
with by low average ΔCt values (high expression levels) in hES/hiPS-g (Fig. 1A, blue 
bar), with the corresponding values in hSomatic-g (Fig. 1A, red bar). The list included the 
miRNAs that were previously reported to be highly expressed in ES or iPS cells, such as 
miR-302 cluster [18,20,21,23,24], miR-17-92 cluster miRNAs [18,21], and C19MC 
members [18], as expected. More than half of the top 50 miRNAs in hES/hiPS-g showed 
higher expression levels than in hSomatic-g. Previous studies have shown that p53 and its 
downstream effector p21 are induced during reprogramming, and minimizing the 
expression of p53 and p21 enhances iPS cell formation [32-36]. The miRNAs that were 
reported to suppress p21 [37] showed high expression levels both in hES/hiPS-g and in 
hSomatic-g (Fig. 1A, purple asterisks). Next, I listed the top 50 miRNAs based on the 
differences in ΔCt values between hES/hiPS-g and hSomatic-g (Fig. 1B). Notably, the list 
contained 28 human-specific miRNAs including 23 members of the C19MC. Since 94 of 
381 miRNAs are human-specific in the array, human-specific miRNAs were enriched in 
the highly expressed group of miRNAs in hES/hiPS-g (56% vs 25%). On the contrary, 
only two human-specific miRNAs were included in the top 50 miRNAs with higher 
expression levels in hSomatic-g than in hES/hiPS-g (Fig. 1C). Members of the let-7 group, 
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which are involved in developmental timing and expressed at higher levels in fibroblasts 
than in ES cells, were on the list (Fig. 1C), as reported previouly [21]. 
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Fig. 1 Comparison of the expression level of miRNAs in human pluripotent stem cells 
and human somatic cells. The expression level of miRNAs in various cells was examined 
by qPCR based array, and the ΔCt value was calculated as described. Average of ΔCt of 
immature ES/iPS (hES/hiPS-g, blue bar) and somatic cells and iPS derived NSCs 
(hSomatic-g, red bar) was calculated with standard deviation. A. Top 50 miRNAs from 
the highest expression level in ES/iPS are shown. miRNAs labeled with “H” are human 
specific miRNAs. B, C. Top 50 miRNAs from biggest difference of ΔCt between 
hES/hiPS-g and hSomatic-g are shown, as well as values in hES/hiPS-g is bigger (B) and 
in hSomatic-g is bigger (C). In A-C. p value: non marked bars < 0.01. * <0.05, ns not 
significant. Purple asterisk indicates miRNAs which have suppressive to p21 expression 
[37]. 
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Analysis of Human miRNA Profiles 
For clustering analysis, I have selected miRNAs that have Ct values greater than 30 in all 
samples. Following that, 118 miRNAs were excluded, and the remaining 263 miRNAs 
were subjected to HC (Fig. 2A) and NMF (Fig. 2B) based on ΔCt values [29]. Result 
showed that both analyses clearly segregate ES/iPS cells from other cells (Fig. 2A, B). 
The somatic cells, which consist of peripheral blood mononuclear cells (PBMC) and  
dermal fibroblast cells, were closely clustered together, but clearly separated from the 
ES/iPS cells. In the ES and iPS cell lines, three of the human ES cell lines were closely 
clustered. However, the clustering did not group the iPS cells based on cell of origin, 
methods, or use of ROCK inhibitor (Fig. 2A). This result suggests causing the iPS cells to 
acquire another set of miRNAs that exclusively belong to the iPS cells. 
Next, I further analyzed the miRNA expression profile using PCA [30,38]. Result showed 
that the first component (PC1) showed clear segregation of ES/iPS and other cells (Fig. 
2C). The second and third components segregated dermal fibroblasts and PBMCs (Fig. 
2C, D). The PCA listed eigenvector values of each miRNAs, and the miRNAs with 
eigenvector values greater than 2 are shown in Table 2. Most of the listed miRNAs are 
members of the miR-302 cluster and two human-specific C19MC clusters (the miR-
371/372/373 and miR-512~ clusters), and these miRNAs were previously reported to be 
expressed in ES and iPS cells [18, 20-24, 39,40]. Among the list, miR-187, 299-3p, 499-
5p, 628-5p, and 888, have not been reported reported to characterize ES or iPS cells. The 
miR-299-3p was previously described in ES [40], but not in iPS cells. Other studies also 
fail to detect miR-299-3p in ES or iPS cells, perhaps because of the insensitivity of the 
microarray technique used [21]. However, in this study, I have clearly showed that miR-
 18 
187, 299-3p, 499-59, 638-5p, and 888 are strongly expressed in all ES/iPS cell lines, but 
not in other cells, including both primary cells and cancer cell lines (Fig. 2E).  
 
 
Table 2: Human miRNAs with eigenvectors of the first component of more than 2 in 
absolute value. 
miRNA eigenvector 
hsa-miR-302b 4.18252 
hsa-miR-519d 3.6681 
hsa-miR-520e 3.60713 
hsa-miR-499-5p 3.46634 
hsa-miR-302c 3.45615 
hsa-miR-299-3p 3.35883 
hsa-miR-512-3p 3.13687 
hsa-miR-302a 3.04599 
hsa-miR-518f 3.03613 
hsa-miR-367 2.74841 
hsa-miR-888 2.64427 
hsa-miR-520g 2.54294 
hsa-miR-372 2.4097 
hsa-miR-517a 2.24895 
hsa-miR-517c 2.19304 
hsa-miR-628-5p 2.18733 
hsa-miR-518b 2.03204 
hsa-miR-187 2.01046 
hsa-miR-525-3p 2.00243 
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Fig. 2 Clustering analyses of the expression pattern of miRNA in human pluripotent cells, 
differentiated cells, and somatic cells. (A) Comparison of relative expression levels of 
263 miRNAs in human pluripotent cells, differentiated cells, and somatic cells. Red 
indicates low expression and green indicates high expression. 
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Fig. 2 Clustering analyses of the expression pattern of miRNA in human pluripotent cells, 
differentiated cells, and somatic cells. (B) Consensus clustering of cells by NMF with two 
metaprofiles. The NMF-transformed miRNA profiles distinguished two clusters. (C, D) 
PCA was done using the same set of miRNA above. The first three components clustered 
cells (the first and second in C, the second and third in D) are shown. The first component 
accounts for 44.90%, the second for 8.83%, and the third for 8.13% of the system 
variance. (E) Expression levels of newly identified miRNAs are shown. 
!
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Analysis of Mouse miRNA Profiles 
As in the human analysis, the Ct values of each miRNA were normalized to mammalian 
U6.  A simple comparison of the average ΔCt values of ES/iPS cells with the average ΔCt 
values of MEF and TTF showed that members of the 290 and 302 clusters are more 
highly expressed in ES/iPS cells than in MEF/TTF (Fig. 3A, B). On the other hand, 
miRNAs that are highly expressed in MEF/TTF are listed in Fig. 3C. Members of let-7 (a, 
b, c, d, e), and 11 other miRNAs (miR-100, -10a, -10b, -132, -143, -181a, -196b, -199a-
5p, -23a, -383, -505) are also listed as miRNA that are expressed at high level in somatic 
cells in human analysis (Fig. 1C). The result suggests that these miRNAs are expressed at 
low levels in pluripotent cells, and conserved in both human and mouse.  
Similar to human clustering analysis, miRNAs with Ct values greater than 30 in all 
samples were excluded. The remaining 201 miRNAs (out of 335 miRNAs) were further 
processed for clustering analysis. Clustering by HC and NMF showed clear separation of 
ES/iPS cells from MEF/TTF, except for ES_CCE cells (Fig. 4A, B). The PCA also 
showed good separation, and the first component (PC1) contributed significantly to 
distinguished these two groups of cells (Fig. 4C, D). The eigenvectors of all miRNAs 
were obtained from PC1, and miRNAs with absolute values greater than 2 are listed in 
Table 3. Among the listed miRNAs, the members of miR-290 and 302 clusters are well 
documented as ES and/or iPS cell-specific miRNAs [41]. However, the miR-133b, 200a, 
23a, and 743b-5p have not been previously mentioned to characterize ES or iPS cells. The 
ΔCt values of these miRNAs showed that the expression of miR-133b and 23a was lower 
in ES/iPS cells than in MEF/TTF, while miR-200a showed much higher expression in 
ES/iPS cells than in MEF/TTF (Fig. 4E). In contrast, miR-743-5p showed no difference, 
 22 
probably because this miRNA had an extremely low value in TTF. However, similar to 
human cell analysis, the PCA failed to segregate iPS and ES to different categories. 
 
Table 3: Mouse miRNAs which have eigenvectors of the first component more than 2 in 
absolute value. 
miRNA eigenvector 
mmu-miR-292-3p 3.42786 
mmu-miR-295 3.33589 
mmu-miR-293 3.05248 
mmu-miR-291a-3p 3.02925 
mmu-miR-302b 2.81198 
mmu-miR-302a 2.572 
mmu-miR-294 2.52447 
mmu-miR-200a 2.51061 
mmu-miR-290-3p 2.36788 
mmu-miR-302d 2.29456 
mmu-miR-367 2.22163 
mmu-miR-302c 2.21755 
mmu-miR-291b-5p 2.01874 
mmu-miR-133b -2.04838 
mmu-miR-23a -2.27597 
mmu-miR-743b-5p -2.2998 
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Fig. 3 Comparison of the expression level of miRNAs in mouse pluripotent stem cells and 
mouse somatic cells. Expression level of miRNAs in various cells was examined by 
qPCR based array, and the ΔCt value was calculated as described. Average values with 
standard deviation of ΔCt of immature mouse ES/iPS are shown in blue bars. Average 
values of ΔCt of MEF and TTF are shown in red bars. A. Top 50 miRNAs from the 
highest expression level in ES/iPS are shown. miRNAs labeled with “M” are mouse 
specific miRNAs. B, C. Top 50 miRNAs from the biggest difference of ΔCt between 
mES/miPS-g and mSomatic-g are shown, as well as values in mES/miPS-g is bigger (B) 
and in mSomatic-g is bigger (C). 
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Fig.% 4A,B:" HC" and" NMF" analyses"
showed" clear" segrega5on" of"
mES/miPS" cells" from" other" cells."
Fig." 4C," E:" The" PCA" analysis"
showed" clear" segrega5on" of"
mES/iPS"and"other"cells."
F i g ." 4E :" New ly" i den5ﬁed"
microRNAs" to" characterized"
mouse"ES/iPS"cells."
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Fig." 4C, E:" The" PCA" analysis"
showed" clear" segrega5on" of"
mES/iPS"and"other"cells."
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Fig. 4 Clustering analyses of the expression pattern of miRNA in mouse pl ripotent cells, 
differentiated cells, nd somatic cells. (A) Comparison of relative expression levels of 
201 miRNAs in mouse pluripotent cells, and somatic cells. Red indicates low expression 
and green indicates high expression. (B) Consensus clustering of cells by NMF with two 
metaprofiles. The NMF-transformed miRNA profiles distinguished two clusters. (C, D) 
PCA was done using the same set of miRNA as above. The first three components 
clustered cells (the first and second in C, the second and third in D) are shown. The first 
component accounts for 41.99%, the second for 16.62%, and the third for 11.08% of the 
system variance. (E) Expression levels of newly identified miRNAs are shown. 
 25 
Identification of miRNAs Distinguishing ES and iPS Cells 
A previous study has shown that ES and iPS cells can be distinguished by gene 
expression signatures [16]. To further analyzed and understand these cells, I further 
focused on identification of miRNAs that can distinguish human ES and iPS cells. For 
that, I conducted HC and NMF analyses using ΔCt values for ES and iPS cells under 
several different sets of conditions. Result showed that both HC or NMF failed to 
separate ES and iPS cells. Further analysis by PCA also produced a similar result, with no 
identification of miRNAs to clearly distinguish human ES and iPS cells. Therefore, I 
decided to perform a simple comparison based on average ΔCt values for ES and iPS 
cells. The miRNAs that showed statistically significant differences between the two 
groups are shown in Figure 5A. Strikingly, most C19MC members showed higher 
expression in iPS than in ES cells (Fig. 5A). A previous study also reported the 
differential expression of miRNAs C19MC, but with higher expression in ES than in iPS 
cells [21]. However, in that study, single types of each ES and iPS cell lines were 
compared, indicating that their result may only be true for that particular type of cell, and 
does not reflect the ES and iPS cells in general. A previous study also identified other 
miRNAs that are differentially expressed in ES and iPS cells. The study by Wilson et al. 
reported that the miR-886-5p was expressed at higher in iPS than in ES cells. However, in 
this study, the average ΔCt values of miR-886-5p was shown to express at similar levels 
in iPS (9.2, SD. 2.8) and ES cells (9.2, SD. 1.7). A study by Chin et al. listed 16 miRNAs 
that are differentially expressed in human ES and iPS cells [16]. However, only three of 
them showed similar trends in our study. The group used oligo DNA-based arrays (Ohio 
State University Comprehensive Cancer Center) to profile their miRNAs, and I cannot 
deny that different miRNA analysis protocols contribute to the different results observed. 
 26 
In mouse cells, comparison of mouse ES and iPS cells identified several miRNAs that are 
expressed at significantly different levels in ES and iPS cells, with members of the let-7 
and miR-30 families more highly expressed in iPS than in ES cells (Fig. 5B). 
 
Fig.%5:"Iden'ﬁca'on"of"miRNAs"highly"regulated"in"ES"and"iPS"cells."
Members"of"Ch19"cluster"are"highly"expressed"in"iPS"than"in"ES"cells"in"human"(A)"while"members"of"letH7"
and"miR30"clusters"are"diﬀeren'ally"expressed"in"mouse"ES/iPS"(B)"
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Fig. 5 Comparison of miRNA expression levels of ES and iPS cells. A, B. Average ΔCt 
of human (A) or mouse (B) ES and human (A) or mouse (B) iPS are shown. miRNAs that 
have less than 0.05 p val e between ES and iPS cells are li te  by their miRNA number. 
Clustered miRNAs are indicated by a violet mark under the bar. p value: non marked bars 
< 0.01. *(red asterisk) <0.05 
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Comparison of Human and Mouse ES/iPS Cell-Specific miRNAs 
Human and mouse ES/iPS cells are in different states of pluripotency. Specifically, mouse 
ES/iPS cells are in naïve pluripotency while human ES/iPS cells are in the primed state 
[42-44]. Mice have primed pluripotent stem cells called epiblast stem cells [4,44], and 
differences in gene expression patterns have been reported. To further compared these 
two types of cells at the miRNA level, I identified miRNAs with the highest expression 
levels (lowest ΔCt values) in human and mouse ES/iPS cells. Figure 6A shows the top 60 
miRNAs in mouse ES/iPS and human ES/iPS cells. Green asterisks indicate 
housekeeping miRNAs, the miRNAs that showed a difference of less than 2 in the ΔCt 
values between ES/iPS-g and somatic-g (Fig. 1). The miRNAs with differences in rank of 
greater than 50 are highlighted in pink. Expression levels (ΔCt) of miRNAs that have a 
difference of more than 50 difference in mouse and human ranking and more than 2 ΔCt 
value difference with somatic cells are shown in Figure 6B. Most of the top-ranked 
miRNAs specific to ES/iPS cells are either mouse-specific or human-specific. In the 
mouse list (Fig. 6A), six of the top eight mouse-specific miRNAs are members of the 
miR-290 cluster. The human miR-371 cluster was predicted to exist based on sequence 
similarity to members of the mouse miR-290 cluster [45,46]. One of the members of the 
miR-371 cluster, the miR-372, is ranked 33rd in the human miRNA list (Fig. 6A). In 
humans, the C19MC were originated evolutionarily from the miR-371-373 cluster [47], 
and some C19MC members were shown to share the same seed sequence with miR-372, 
373, and other ES/iPS enriched miRNAs such as miR-302 cluster [48,49]. Members of 
the miR-302 cluster were ranked 11th, 17th, 34th, and 59th in the mouse list, and 1st, 
30th, and 33rd in the human list. On the other hand, the miR-367, which is a distantly 
related member of the miR-302 cluster [45], was 37th in the mouse list and 17th in the 
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human list. This indicates that large numbers of miRNAs that are orthologs or have an 
identical seed sequence are among the most abundant miRNAs in both mice and humans. 
A previous study has shown that miR-302, miR-372, and miR-292 share redundant 
activity by targeting to TGF-β, and promotes cells reprogramming [46]. In addition, 
members of the miR-17 cluster and the miR-302 cluster, which share the same sequence, 
were also shown to mediate reprogramming by targeting TGFβr2 and p21 during the 
mesenchymal-to-epithelial transition during the initiation stage of reprogramming [13]. 
The miR-182, 708, and 499-5p, which showed a large difference of expression between 
human iPS/ES and somatic cells, showed very little difference in mouse case (Fig. 6B). 
However, previous literature did not explain the specific expression of these miRNAs in 
human and mouse pluripotent cells.  
 
 
 
 
 
 
Fig. 6 Comparison of miRNAs between human and mouse pluripotent stem cells 
(A) The top 60 miRNAs from the lowest average ΔCt value of human and mouse 
pluripotent stem cells are listed. Ranking number in human and mouse are compared, and 
additional information is indicated in the panel below of the figure. (B) Expression levels 
(ΔCt) of miRNAs which are differentially expressed in human and mouse ES/iPS. Listed 
miRNAs are labeled with pink color but not with green asterisk in the panel A, which 
means there are miRNAs with more than 50 differences in mouse and human ranking, 
and at the same time, have more than 2 ΔCt value difference with somatic cells. 
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Fig.% 6:% Comparison" of" miRNAs" highly"
regulated"in"ES/iPS"than"in"other"cells."
(A)  Top"60"miRNAs"highly" expressed" in"
human"and"mouse"ES/iPS"cells"were"
shown."The"miRNAs"were"compared"
based"on"ranking"in"both"species.""
(B)  Expression" levels" (∆Ct)" of" selected"
miRNAs" which" are" diﬀeren'ally"
expressed"in"human"and"mouse"ES/
iPS.""
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22' mmu8miR8200b' 26' *"hsa8miR8222' 71'
23' mmu8miR8200a' 72' hsa8miR8374b'
24' mmu8miR8182' 203' hsa8miR825'
25' *"mmu8miR831' 55' *"hsa8miR816' 10'
26' *"mmu8miR8210' 63' hsa8miR8200b'
27' mmu8miR8429' 77' hsa8miR8523'
28' mmu8miR829083p' hsa8miR8135b' 13'
29' *"mmu8miR893' 42' hsa8miR 518d83p'
30' *"mmu8miR8672' 59' *"hsa8miR8191' 15'
31' mmu8miR8367' 6' hsa8miR820b' 19'
32' *"mmu8miR830c' 40' *"hsa8miR824' 14'
33' *"mmu8miR8140' 98' hsa8miR8372'
34' mmu8miR8302d' *" *"hsa8miR8484' 12'
35' *"mmu8miR834b83p' *" *"hsa8miR829a'
36' *"mmu8miR857483p' *"hsa8miR834c85p' 210'
37' *"mmu8miR826a' 43' hsa8miR8519a'
38' *"mmu8miR83 583p' hsa8miR8146a'
39' mmu8miR8200c' 18' hsa8miR8517b'
40' *"mmu8miR 328' 189' *"hsa8miR830c' 32'
41' *"mmu8miR821' 41' *"hsa8miR821' 41'
42' *"mmu8miR829a' 35' *"hsa8miR893' 85'
43' *"mmu8miR8127' 169' *"hsa8miR826a' 37'
44' *"mmu8miR8130a' 96' *"hsa8miR892a' 16'
45' mmu8miR8183' 138' *"hsa8miR8374a'
46' mmu8miR8134' 260' hsa8miR8141' 205'
47' mmu8miR8152' 215' *"hsa8miR8106b' 77'
48' *"mmu8miR8136' 258' *"hsa8miR83 183p' 99'
49' *"mmu8miR840983p' *" *"hsa8miR8454'
50' *"mmu8miR8467e' *"hsa8miR8186' 86'
51' *"mmu8miR832383p' 168' *"hsa8miR8425' 126'
52' mmu8miR8291b85p' *"hsa8miR8107' 303'
53' mmu8miR8150' 186' *"hsa8miR8193b' 82'
54' *"mmu8miR8467b' *"hsa8miR8221' 136'
55' *"mmu8miR8433' 211' *"hsa8miR831' 25'
56' *"mmu8miR8467a' *"hsa8miR834a' 65'
57' *"mmu8miR8199a83p' 110' hsa8miR8487a' *"
58' *"mmu8miR8494' 154' hsa8miR 518e'
59' mmu8miR8302c' 15' hsa8miR8672' 30'
60' mmu8miR8367c' 243' hsa8miR8519c83p'
Remarks'
all'listed'miRNAs'are' ighly'expr ssed'in'mouse'and'human'with'less'
than'50'diﬀer nce'in'ra king' xcept'for:'
''
miRNA'with'more'than'50'diﬀer nce'in'mouse'and'human'
ra king'
'' mouse'or'human'speciﬁc'
all'miRNAs'have'ΔCt'value'more'than'2'diﬀer nce'with'somaLc'cells'
(expression'level:'ES/iPS'>'somaLc'cells)' xcept'for:'
*'
miRNA'having'ΔCt'more'than'2'diﬀer nce'with'somaLc'cells'
(expression'level:'ES/iPS'<'somaLc'cells)'
*'
miRNA'having'less'than'2'ΔCt'value'diﬀer nce'with'somaLc'
cells'
*'a'primer'is'not'available'in'the'array'
miRNA'indicated'as' igher'expression'(from'Jouneau'et'al.'RNA' 012)'
*'in'ESCs'than'EpiSCs'
*'in'EpiSCs'than'ESCs'
Ranking'from'
lowest'ΔCt' mouse'miRNA'
Ranking'in'
human' human' iRNA'
Ranking'in'
mouse'
1' mmu8miR 292 3p' hsa8miR 302b' 11'
2' *"mmu8miR 19b' 8' hsa8miR 519d'
3' mmu8miR 295' hsa8miR 62 5p'
4' *"mmu8miR 106a' 10' hsa8miR 88 '
5' mmu8miR 293' hsa8miR 51 f'
6' *"mmu8miR 19a' 17' hsa8miR 367' 31'
7' *"mmu8miR 17' 9' hsa8miR 517c'
8' mmu8miR 291a83p' *"hsa8miR 19b' 2'
9' *""*"mmu8miR 20a' 12' *"hsa8miR 17' 7'
10' *"mmu8miR 16' 25' *"hsa8miR 106a' 4'
11' mmu8miR 302b' 1' hsa8miR 299 3p' *"
12' *"mmu8miR 484' 34' *"hsa8miR 20a' 9'
13' mmu8miR 135b' 28' hsa8miR 512 3p'
14' *"mmu8miR 24' 33' *"hsa8miR 302a' 17'
15' *"mmu8miR 191' 30' *"hsa8miR 302c' 59'
16' *""*"mmu8miR 92a' 44' hsa8miR 520e'
17' mmu8miR 302a' 14' *"hsa8miR 19a' 2'
18' *"mmu8miR 687' hsa8miR 200c' 39'
19' mmu8miR 20b' 31' hsa8miR 520g'
20' mmu8miR 294' hsa8miR 70 ' 98'
21' *"mmu8miR 667' hsa8miR 499 5p' 241'
22' mmu8miR 200b' 26' *"hsa8miR 222' 71'
23' mmu8miR 200a' 72' hsa8miR 374b'
24' mmu8miR 182' 203' hsa8miR 25'
25' *"mmu8miR 31' 55' *"hsa8miR 16' 10'
26' *"mmu8miR 210' 63' hsa8miR 200b'
27' mmu8miR 429' 77' hsa8miR 523'
28' mmu8miR 290 3p' hsa8miR 135b' 13'
29' *"mmu8miR 93' 42' hsa8miR 51 d83p'
30' *"mmu8miR 672' 59' *"hsa8miR 191' 15'
31' mmu8miR 367' 6' hsa8miR 20b' 19'
32' *"mmu8miR 30c' 40' *"hsa8miR 24' 14'
33' *"mmu8miR 140' 98' hsa8miR 372'
34' mmu8miR 302d' *" *"hsa8miR 484' 12'
35' *"mmu8miR 34b p' *" *"hsa8miR 29a'
36' *"mmu8miR 574 3p' *"hsa8miR 34c85p' 210'
37' *"mmu8miR 26a' 43' hsa8miR 519a'
38' *"mmu8miR 335 p' hsa8miR 146a'
39' mmu8miR 200c' 18' hsa8miR 517b'
40' *"mmu8miR 32 ' 189' *"hsa8miR 30c' 32'
41' *"mmu8miR 21' 41' *"hsa8miR 21' 41'
42' *"mmu8miR 29a' 35' *"hsa8miR 93' 85'
43' *"mmu8miR 127' 169' *"hsa8miR 26a' 37'
44' *"mmu8miR 130a' 96' *"hsa8miR 92a' 16'
45' mmu8miR 183' 138' *"hsa8miR 374a'
46' mmu8miR 134' 260' hsa8miR 141' 205'
47' mmu8miR 152' 215' *"hsa8miR 106b' 77'
48' *"mmu8miR 136' 258' *"hsa8miR 331 p' 99'
49' *"mmu8miR 409 3p' *" *"hsa8miR 454'
50' *"mmu8miR 467e' *"hsa8miR 186' 86'
51' *"mmu8miR 323 p' 168' *"hsa8miR 425' 126'
52' mmu8miR 291b85p' *"hsa8miR 107' 303'
53' mmu8miR 150' 186' *"hsa8miR 193b' 82'
54' *"mmu8miR 467b' *"hsa8miR 221' 136'
55' *"mmu8miR 433' 211' *"hsa8miR 31' 25'
56' *"mmu8miR 467a' *"hsa8miR 34a' 65'
57' *"mmu8miR 199a83p' 110' hsa8miR 487a' *"
58' *"mmu8miR 494' 154' hsa8miR 51 e'
59' mmu8miR 302c' 15' hsa8miR 672' 30'
60' mmu8miR 367c' 243' hsa8miR 519c83p'
Remarks'
all'listed'miRNAs'are'highly' xpr ssed'in'mouse'and'human'with'less'
than'50'diﬀerence'i 'ranking except'for:'
''
miRNA'with'more'than'50 diﬀerence'i 'mouse'and'human'
ranking'
'' mouse'or'h man'speciﬁc
all'miRNAs'have'ΔCt'value'more'than'2'diﬀerence'with'somaLc'cells
(expr ssion'level:'ES/iPS'>'somaLc'cells)' x pt'for:'
*'
miRNA'having'ΔCt'more'than'2'diﬀerence'with'somaLc'cells
(expr ssion'level:'ES/iPS'<'somaLc'cells)'
*'
miRNA'having'less'than'2'ΔCt'value'diﬀ rence'with'somaLc'
cells'
*'a'prime 'is'not'avail ble'in'the'array'
miRNA'indicated' s'higher'exp ssion'(from'J unea 'et'al.'RNA 2012)'
*'in'ESCs'than'EpiSCs'
*'in'Ep SCs'than'ESCs'
ranking*
in*human*
ranking*
in*mouse*
human*
miRNA*
mouse*
miRNA*
ranked*
based*on*
expression*
*
*
iRNAs*that*are*highly*regulated*in*previous*
report*(Jouneau*et*al,*2012,*RNA)*
**higher*in*ES*than*EpiSCs*
**higher*in*EpiSCs*t an*ES*
*
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Changing Levels of miRNAs when iPS cells Differentiated 
Next, I examined the expression levels of miRNAs during iPS cells differentiation (Fig. 
7). The iPS cells were differentiated through the formation of EBs, and the differentiated 
cells were harvested at three different time points. The expression levels of most of the 
miRNA were drastically changed after EB formation, and the miRNAs were divided into 
two groups: downregulated (Fig. 7A–D) and upregulated (Fig. 7E–G) after EB formation. 
Figure 7A shows miRNAs that were expressed at high levels in human ES/iPS cells 
(denoted by immature EBs, d 0) and at low levels in EBs at day 7, 14, and 21). One of the 
miRNAs in the list, the miR-369-3p, was previously reported to reprogram human and 
mouse cells to pluripotency by direct transfection of mature double stranded miRNAs 
[31]. The newly identified ES/iPS cell-specific miRNAs, miR-299, -499-5p, -628-5p, and 
-888, were also included in the list, further showing that these miRNAs are more highly 
expressed in immature cells than in differentiating or differentiated cells, and may be 
useful for iPS cells reprogramming. Another group of miRNAs were expressed  at high 
levels in immature EBs, but showed decreased expression at day 7; these later increased 
when the cells underwent further differentiation at days 14 and 21 (Fig. 7B). Similarly, 
miRNAs shown in Figures 7C and 7D were expressed at a high level in iPS cells but 
showed a significant decrease in expression on day 7. Some miRNAs were upregulated as 
the cells differentiated on day 14 and 21 (Fig. 7C), while some miRNAs constantly 
expressed at low levels on both day 7 and day 14 and only increased at al later stage of 
differentiation (Fig. 7D). By contrast, the miRNAs that are important in the regulation of 
cell differentiation were expressed at a low level in immature iPS cells but showed 
significantly increased expression on day 7 and at a later stage of differentiation (Fig. 7E). 
The other groups of miRNAs were lowly expressed in both immature cells and cells at an 
 31 
early stage of differentiation but significantly increased on day 14 and remained 
expressed at a high level on day 21 of differentiation (Fig. 7F, G). The members of the 
let-7 cluster, which were previously reported on [40,50,51], showed sharp increases in 
their miRNA expression on day 7 of differentiation and remained expressed at a later 
stage of differentiation (Fig. 7H). The differential expression of miRNAs observed during 
iPS cell differentiation shows that miRNAs are highly regulated in pluripotent cells and 
play an important role in regulating cell differentiation. 
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Fig. 7 Alteration of level of miRNAs during formation of human EB. Human EB was 
formed, and the expression profile of miRNAs was examined at days 7, 14, and 21 after 
starting the formation of EB. Levels of miRNAs were categorized by patterns of changing 
of expression (ΔCt values). 
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Discussion 
miRNA has received much attention in recent years in basic and applied science. For 
pluripotent cells, miRNA is expected to be a powerful tool from a technical perspectives 
as well as in terms of biological interests. Profiling miRNA expression patterns in ES and 
iPS cells is critical. Several technologies are available for miRNA profiling, and each of 
them may be better than others in terms of sensitivity, cost efficiency, sequence 
dependence, or avoidance of potential contamination by artifacts. The selection of a 
technique with a different approach and experimental setting may explain the 
fundamental differences observed, especially when a variety of pluripotent and 
differentiated cells from different species is used. Thus, for this study, I took advantage of 
a miRNA array system that offers a consistent setting when applied to different types of 
cells in both humans and mice. Thus far, no study had profiled miRNA expression in 
human and mouse ES and iPS cells at the same time. Hence, I comprehensively analyzed 
miRNA expression patterns in purified ES and iPS cells and somatic cells, in both 
species. As I am attempted to establish a reliable database, I carefully examined the 
reproducibility of the results obtained by the qPCR-based method and the effects of 
sample preparation on the quality of the results. I found that RNA prepared from a 
mixture of iPS cells and feeder cells gave weaker signals than RNA obtained from 
purified iPS cells. Therefore, I prepared all pluripotent cells by purification, using a cell 
sorter and SSEA-4 (human) or SSEA-1 (mouse) antibody. The resulting comprehensive 
data allowed me to compare different subsets of pluripotent cells and identify several 
miRNAs that had not previously been reported to characterize ES/iPS cells.  
In this study, I have identified miR-187, 299-3p, 499-5p, 628-5p, and 888 as new 
miRNAs to distinguish between pluripotent and non-pluripotent cells. These miRNAs 
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showed nearly negligible values or were not examined in previous studies [21,22]. An 
interesting question to ask is: Why was this study able to identify these miRNAs, and why 
were others unable to do so? The answer may lie in the technique used for analysis in this 
study: a very stable, high-sensitivity analysis was applied. The iPS cells cultured on MEF 
feeder cells were sorted for SSEA-4 or SSEA-1 to ensure that there was no contamination 
of cells from the feeder cells. The purification of cells is necessary as cDNA isolated from 
feeder cells can dilute the absolute number of miRNAs present in the iPS cells. So far, no 
other study has employed this purification method for miRNA expression profiling. This 
may further answer why I can identify the miR-187, 299-3p, 499-5p, 628-5p, and 888. 
Another important issue to clarify is whether or not the identification of these miRNAs 
was influenced by the selection of cells used as a control. In this study, I am using various 
types of ES and iPS cells. I am comparing them with non-pluripotent cells consisting of 
peripheral blood, human-dermal fibroblast cells, iPS-derived EBs, iPS-derived NSCs and 
several epithelial-associated cancer cells. As such, does this analysis, which includes 
samples from cancer cells, interfere with the overall miRNA expression profile and 
contribute to the identification of miR-187, 299-3p, 499-5p, 628-5p, and 888? To answer 
the question, I used a similar experimental setting with PCA and analyzed the samples 
without the cancer cell line, HEK293, Y79, and Hela. As a result, I observed a similar 
trend in cell distribution where PCA clearly showed a clear segregation of ES/iPS cells 
with other non-pluripotent cells. These two groups of cells were distinguished by PC1 
with the same list of miRNAs as recorded in Table 2, except for miR-187. The miR-187 
showed an eigenvectors value of 1.86, less than 2, which is the minimum number I had 
selected to distinguish pluripotent and non-pluripotent cells. The eigenvector values from 
this PCA showed that the selection of cells used as a control has little impact on the final 
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outcome that contributes to the identification of miR-187, 299-3p, 499-59, 628-5p, and 
888. In a different view, I also applied a similar PCA to the ES/iPS cells and compared it 
with control cells consisting of only HDF and PB cells. The HDF and PB cells were 
selected as controls since all iPS cells used in this work were reprogrammed from 
fibroblast and blood-related cells. Interestingly, I obtained similar results as observed in 
the first data analysis indicating that the newly identified miRNAs are indeed highly 
expressed in ES/iPS rather than in non-pluripotent cells. Moreover, the selection of cells 
as controls do not significantly contribute to the identification of miR-187, 299-3p, 499-
5p, 628-5p, and 888. 
To predict the regulatory activities of newly identified miRNAs, I focused on identifying 
the seed sequence of the miRNAs, which is responsible for binding to the 3’UTRs of 
target genes. The seed sequence of the newly identified miRNAs was compared with 
known ES/iPS-specific miRNAs. Most of the known pluripotent-specific miRNAs shared 
the same seed sequence, which demonstrated a redundant function of these pluripotent-
specific miRNAs. The seed sequence of AAGUGC is shared among miR-302b-3p, miR-
373, miR-520e, miR-519c-3p, miR-520a-3p, and miR-520b; AGUGCC in miR-371-3p, 
miR-515-3p and miR-519e; and AAGUG in miR-17, 201a, 93, 106a, 106b, 20b and 519d. 
However, none of the newly identified miRNAs shared the same seed sequence with 
these known pluripotency-specific miRNAs. Among all listed miRNAs highly expressed 
in pluripotent cells (Fig. 1A), miR-200c does not share any seed sequence with the 
ES/iPS-specific miRNAs but has been shown to induce cell reprogramming. Meanwhile, 
the miR-200c, with a seed sequence of AAUACUG, was reported to work together with 
miR-302 to induce iPS cell reprogramming using mature, double-stranded miRNAs [32]. 
The regulatory activity shown by miR-200c with miR-302 proved that miRNAs are 
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highly expressed in pluripotent cells but do not possess the same seed sequence as 
ES/iPS-specific miRNAs still playing an important roles in regulation of reprogramming 
and perhaps in the maintenance of pluripotency. These miRNAs may work in 
combination with ES-specific miRNAs to regulate certain genes during reprogramming, 
maintenance of self-renewal, or regulation of cell differentiation. 
Pluripotent cells share characteristics with tumor cells in several different ways. For 
example, both cells have been shown to form teratomas when injected into nude mice, 
and these criteria have been commonly used to characterize iPS cell pluripotency [2,3]. In 
regards to reprogramming, suppression of p53 and UTF1, which are disrupted in tumor 
cells, have been shown to accelerate and induce reprogramming [34,66]. In addition, the 
reprogramming factors such as c-myc, Klf-4, and Nanog are oncogenes that were 
dysregulated in various types of cancer [67-69]. Hence, it is not surprising to see miRNAs 
specifically expressed in ES cells playing important roles in the regulation of cancer cells 
[70-72]. Several studies have reported miR-302 cluster to be overexpressed in germ-cell 
tumors and may serve as a potential serum bio-marker [73]. In addition, miR-302 cluster 
was also reported to regulate self-renewal and proliferation of glioma-initiating cells, 
cervical carcinoma cells, and endometrial cancer cells [74-76]. The regulatory activities 
of the miR-302 cluster showed that miRNAs highly expressed in pluripotent cells have 
redundant activities in cancer cells. Interestingly, the newly identified miRNAs, miR-187, 
299-3p, 499-5p, 628-5p, and 888 were also reported in association with diseases and 
cancers in various papers and databases such as miR2diseaseBase and HMDD [52-55, 70-
72]. However, whether or not these newly identified miRNAs are important with regard 
to iPS or ES cells still remains unanswered. 
 37 
In this study, I found that the newly identified miRNAs were expressed at high levels in 
pluripotent cells but not in non-pluripotent cells. With the exemption of miR-187, all 
newly identified miRNAs were in the top 21 miRNAs that were highly expressed in 
pluripotent cells. The miR-628-5p and miR-888 were at rank 3 and 4, respectively. This 
indicates that these miRNAs may be expressed at high levels in order to control various 
genes in association with pluripotency. To clarify further the roles of miR187, 299-3p, 
499-59, 628-5p and 888, I identified their potential target genes using several public 
databases. These included miRanda, miRDB, miRWalk, RNA22 and TargetScan 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html). The databases 
predicted various physiological functions for the miRNAs associated with cell-cycle 
regulation, cell growth, apoptosis, cell differentiation, and other factors, which were 
previously reported to be regulated during cell reprogramming [46]. The miR-499-5p was 
predicted by the microRNA.org database to regulate CDK19, which involves cell-cycle 
regulation, RAB5C in vesicular transport, and ARHGAP26 in the cell-signaling process 
[77]. These predicted target genes of miR-499-5p were shown to down-regulate during 
cell reprogramming suggesting that upregulation of miR-499-5p during cell transition 
from somatic to pluripotent is necessary to regulate reprogramming process. 
The functional activities of miRNAs can be verified via several means based on three 
main subjects: reprogramming, maintenance of pluripotency, and determination of cell 
lineage. The analysis can be performed by manipulating endogenous levels of miRNAs 
using the overexpression or knockdown approach, through a plasmid-based method, or 
via a commercially available short-stranded miRNA mimic or antagonist. In the 
reprogramming process, somatic cells such as fibroblast cells can be used as a 
reprogramming source. The cells can be reprogrammed with miRNAs in the presence or 
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absence of commonly used OSKM transcription factors. The reprogramming factors can 
be delivered to the cells using several methods [10-14]. Meanwhile, the effect of miRNAs 
on the efficiency of reprogramming can be monitored by observing the number of iPS cell 
colonies. Moreover, the quality of the generated iPS cells can be evaluated through 
several means as previously discussed [2,3,5]. In regards to self-renewal and pluripotency, 
the same evaluation methods in combination with an analysis at the molecular level can 
be applied to the established iPS cells that were overexpressed or suppressed with the 
miRNAs [15]. In order to study the effect of miRNAs during the regulation of cell 
differentiation, the manipulated iPS can be cultured in the absence of feeder cells or 
growth factors such as LIF or b-FGF. The regularly used method involves inducing the 
cells to differentiate into embryoid bodies, which allows the cells to differentiate into all 
three main germ layers that develop during embryogenesis: the ectoderm, endoderm, and 
mesoderm [78]. The effect of miRNAs during iPS cell differentiation can be accessed 
using qRT-PCR or immunohistochemistry by examining the expression of pluripotency 
marker such as Rex1 or Nanog, and cell specific marker such as Pdx1, Sox9 or Ngn3 [25]. 
Specifically, the process is carried out by measuring the level of pluripotency markers or 
cell-specific markers as mentioned earlier [79,80]. Exploring the regulatory activities of 
these newly identified miRNAs might unravel new molecular mechanisms that underly 
iPS cell reprogramming, the maintenance of self-renewal, and differentiation.  
Differences in miRNA expression patterns between ES and iPS cells were one of the 
focuses of the current study. At first, I used the clustering and PCA methods to segregate 
ES and iPS. However, the analysis failed to segregate ES and iPS cells. Hence, I further 
analyzed the cells by comparing the two groups of cells based on ΔCt. Simple comparison 
of average values for human ES and iPS cells identified several miRNAs with statistically 
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significant differences in expression between those group of cells. Among them, C19MC 
members showed higher expression levels in iPS than in ES cells. C19MC harbors the 
largest cluster of miRNA genes that developed in a recent mammalian evolution [47,56]. 
It spans a genomic region of about 100 kb, which contains 39 miRNAs. A common 
enhancer for C19MC miRNAs may contribute to differences in the expression levels 
between ES and iPS cells; however, mechanisms regulating C19MC miRNA transcription 
have not been well characterized. C19MC originated evolutionally from the miR-371-373 
cluster, the human ortholog of the mouse 290 cluster [47]. However, the miR-371-373 
cluster (humans and mice) and miR-290 cluster (mice) did not show significant 
differences in expression between iPS and ES. The presence of abundant miRNA with 
similar seed sequences in C19MC indicates the generation of novel miRNAs during 
primate evolution, which may have led to functional diversification [47]. Therefore, 
higher expression of C19MC members, but not human miR-371-373 or mouse miR-290 
members, in iPS cells indicates that the acquired functions of C19MC members may 
contribute to the biological significance of different expression levels in ES and iPS cells. 
Through examination of the SD values, I found that most miRNAs that show statistically 
significant differences between ES and iPS cells have relatively high SD values. In this 
study, I had analyzed large numbers of cells and detected statistically significant 
differences in several miRNAs. However, whether these differences reflect the difference 
between ES and iPS cells should be examined carefully. Previous works at the gene 
expression profiles suggested that ES and iPS cells are distinctly different [17, 81]. 
However, more recent work focusing on the global chromatin structure and gene 
expression data of ES and iPS cells showed that the transcriptional programs of ES and 
iPS cells exhibit little variation and did not serve to distinguish ES from iPS cells [15]. 
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The variation or similarities observed may be due to the cells or methods used for the 
analysis, which may answer why current findings contradict each other. 
By analyzing miRNAs in both human and mouse pluripotent cells, I sought to identify 
differences in miRNA expression patterns between humans and mice. I am concerned as 
to whether a comparison of Ct values obtained using different primers (human and 
mouse) would give meaningful results, but the ranks of miRNAs were quite similar in 
humans and mice (Figs. 1, 3). This is probably because the qPCR conditions for each 
primer set were well adjusted to give proper Ct values, as the supplier claimed. Among 
common human and mouse miRNAs, not many miRNAs showed significant differences 
in expression between humans and mice. Whether these miRNAs correlate with the 
differences in pluripotency levels between humans and mice is an interesting issue. 
Previous work examining miRNA expression in naïve (ES cells) and primed (epiblast 
stem cell, EpiSC) mouse pluripotent stem cells revealed that several distinct miRNAs are 
differentially expressed in ES cells and EpiSCs [57]. Hierarchical clustering of miRNA 
expression profiles in two ES cells lines and three EpiSC lines showed that the three 
EpiSC samples clustered closely together and could be discriminated from the ES cells 
[57]. Among 987 miRNAs whose expression differed between ES cells and EpiSCs, 226 
miRNAs were more highly expressed in ES cells, while 76 miRNAs were more highly 
expressed in EpiSCs [57]. However, among the most abundant differentially expressed 
miRNAs (19 miRNAs with higher expression in ES cells and 22 miRNAs with higher 
expression in EpiSCs), three and four miRNAs that are more highly expressed in ES and 
iPS cells, respectively, showed similar trends in our comparison of human and mouse 
miRNAs (Fig. 6). However, further characterization of these miRNAs are necessary to 
improve understanding of the molecular mechanisms underlie stem cell pluripotency. 
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Conclusion 
MiRNA expression pattern of various types of pluripotent and non-pluripotent cells 
analyzed by qRT-PCR based miRNA profiling showed clear separation of two major 
clusters, ES/iPS cells and other cell group, demonstrating that miRNA have significant 
roles in defining cells identity. Further analyses lead to identification of new miRNAs that 
characterized human ES/iPS cells, miR-187, 299-3p, 499-5p, 628-5p, and 888. Several 
miRNAs including chromosome 19 miRNA cluster found to be more strongly expressed 
in human iPS cells than in ES cells. Similar analyses conducted in mouse ES/iPS cells 
and somatic cells also suggest differentially expressed miRNAs in ES and iPS cells. Time 
course tracing of miRNA levels during embryoid body formation further highlight the 
regulatory activities of miRNAs during development. Expression pattern of the miRNA 
may serve as a valuable tool evaluate the level of pluripotency among ES and iPS cells, 
and it may suggest that miRNAs are a functionally important molecule to regulate iPS or 
ES cells pluripotency and differentiation. Further understanding of miRNA regulation in 
combination of gene expression profiling may provide a better understanding to the 
mechanisms involved in regards to cells reprogramming, maintenance of pluripotency 
and regulation of cells differentiation. 
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